DLBCL Video Channel
Explore the latest insights and summaries from experts in DLBCL.
Therapeutic Agents
Dipenkumar Modi
Current Management of DLBCL From Frontline to Relapsed Disease
- 334 views
- June 5, 2024
Rush University Medical Center
Off the Shelf CARs for DLBCL: Myths and Facts
FEATURING
Veronika Bachanova
- 28 views
- June 6, 2024
Gerardo Musuraca
Managing R/R DLBCL: Bispecific Antibodies and the "Surface Epitopes Strategy"
- 72 views
- June 17, 2024
Wojciech Jurczak
Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial
- 343 views
- June 26, 2024
SOHO Brazil 2024
Summary of Updates in R/R DLBCL Treatment
FEATURING
Alvaro Alencar
- 109 views
- July 11, 2024
SOHO Brazil 2024
What Is the Best Timing for Bispecific Antibodies and CAR-T Therapy in LBCL?
FEATURING
Andrew Zelenetz
- 57 views
- July 11, 2024
Vanderbilt University Medical Center (VUMC)
CAR-T for Lymphoma: The Impact of Cell Therapy and Future Challenges
FEATURING
Sattva Neelapu
- 27 views
- July 18, 2024
UChicago Medicine
The Next Frontier of Targeted Therapy in Lymphoma
FEATURING
Kami Maddocks
- 237 views
- July 22, 2024
UChicago Medicine
Exploring the Value of PI3K in Lymphoma Treatment
FEATURING
Changchun Deng
- 18 views
- July 22, 2024
UChicago Medicine
Targeting BTK in B-Cell NHL: Pros and Cons of Inhibitors and Degraders
FEATURING
Adam Kittai
- 48 views
- July 22, 2024
- 1
UChicago Medicine
Bispecifics for LBCL: Guidance for Management of Toxicities in the Community
FEATURING
Jennifer Crombie
- 170 views
- July 29, 2024
- 3
UChicago Medicine
The Evolving Role for Bispecific Antibodies in B-Cell Lymphoma
FEATURING
Tara Mccabe
- 43 views
- July 29, 2024
Yasmin Karimi
FDA Approval of Epcoritamab in R/R FL: What You Need to Know
- 283 views
- August 12, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current Overview of Biscpecific Antibodies in Hematologic Malignancies
FEATURING
Bahar Uncu Ulu
- 50 views
- August 15, 2024
Joseph McGuirk
Liso-Cel in R/R DLBCL: Real-World Insights From the Cell Therapy Consortium
- 53 views
- August 27, 2024
MyCancerHaven
Experts Discuss the Use of CAR-T in 2L DLBCL
FEATURING
Ravi Vij,
Dipenkumar Modi
- 66 views
- August 30, 2024
MyCancerHaven
Recent Updates on Liso-Cel in R/R DLBCL & MCL
FEATURING
Ravi Vij,
Forat Lutfi
- 44 views
- August 30, 2024
Houston Methodist
What's Current in Immunotherapy in DLBCL and FL
FEATURING
Amitkumar Mehta
- 104 views
- September 10, 2024
University of Colorado Department of Medicine
Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Going?
FEATURING
Jonathan Gutman
- 294 views
- September 19, 2024
- 2
Patrizia Mondello
Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLBCL
- 184 views
- September 30, 2024
Amit Mehta
Tafasitamab/Lenalidomide for DLBCL: Which Patients and What to Expect
- 127 views
- October 9, 2024
- 3
Sarah Rutherford
Optimizing 2L DLBCL Treatment Strategies for CAR-T Ineligible Patients
- 66 views
- October 15, 2024
Vanderbilt University Medical Center (VUMC)
Updates in CAR-T Therapy for Aggressive Lymphomas
FEATURING
Bhagirathbhai Dholaria
- 97 views
- October 23, 2024
- 1
Joseph Mikhael
The Relapsed and Refractory MM Patient: When Immune Approaches Are Ineffective
- 100 views
- November 10, 2024
- 2
MyCancerHaven
How I Use CAR T-Cells in Lymphoma
FEATURING
Ravi Vij,
Abhinav Deol
- 61 views
- April 10, 2024
Indy Hematology Review
Immune Effector Cell Therapy for Lymphoid Malignancies: What to Do and Know in Community Oncology Practice
FEATURING
Tycel Phillips
- 152 views
- April 23, 2024
Indy Hematology Review
Current Advances in the Treatment of Aggressive B- and T-Cell Lymphomas
FEATURING
Sonali Smith
- 665 views
- April 23, 2024
- 7
Yale Cancer Center
Yale Cancer Center Updates on B-Cell Lymphomas: Exploring MCL, DLBCL, FL, and CLL/SLL
FEATURING
Shalin Kothari
- 132 views
- May 13, 2024
Yale Cancer Center
Updates on Cellular Therapy Advances in Lymphoma
FEATURING
Iris Isufi
- 86 views
- May 15, 2024
Rush University Medical Center
Advancements in Richter's Transformation: Novel Agents and Cellular Therapies
FEATURING
Farrukh Awan
- 47 views
- June 13, 2024
Juan Pablo Alderuccio
Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial
- 229 views
- July 8, 2024
- 1
Moffitt Cancer Center
R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?
FEATURING
Julio Chavez
- 826 views
- March 4, 2024
- 4
Moffitt Cancer Center
Hot Off the Press: Experts Discuss the Latest Data in Lymphoid Diseases
- 46 views
- March 11, 2024
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: Cell Therapy
FEATURING
Marcos de Lima
- 183 views
- March 26, 2024
- 3
Zachariah DeFilipp
Axatilimab in Chronic GVHD: Updates From the AGAVE-201 Study
- 187 views
- March 27, 2024
Scripps Health
Update in the Treatment of R/R DLBCL
FEATURING
Charalambos Andreadis
- 234 views
- March 28, 2024
- 2
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: Aggressive B-Cell Lymphomas
FEATURING
Grzegorz Nowakowski
- 395 views
- March 29, 2024
- 3
UChicago Medicine
Understanding CRISPR and Gene Editing in the Treatment of Heme Malignancies and Blood Disorders
FEATURING
Alan Cooper
- 255 views
- July 29, 2024
Yale Cancer Center
The Role of Radiation in Patients Undergoing CAR T-Cell Therapy for Aggressive Lymphomas
FEATURING
Timothy Robinson
- 8 views
- October 28, 2024
UChicago Medicine Jonas Center Cellular Therapy Symposium
Avoiding Alloreactive T-Cells to Enable Off-the-Shelf Therapy for Lymphoma
FEATURING
Cliona Rooney
- 5 views
- December 4, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Optimizing Tafa-Len in R/R DLBCL - GELTAMO Real-World Study
FEATURING
Antonio Gutierrez
- 13 views
- December 16, 2024
- 1